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Intramuscular buprenorphine compared
with morphine for postoperative analgesia
K. A. PAYNE, W. B. MURRAY, H.BARRETT
Summary
The postoperative analgesic efficacy of buprenor-
phine (Temgesic; R & C Pharmaceuticals) 0,004
mg/kg andmorpl1ine 0,15 mg/kg were compared in
60 patients, both agents given by intramuscular injec-
tion. According to patients, buprenorphine gave better
analgesia. There was no difference in the number of
analgesic injections the two groups received in the
24-hour postoperative period. cardiovascular and
respiratory· systems were not depressed by either
drug. Side-effects were not marked, nausea I:leing
the most common in both groups. Morphine had a
- greater effect on the mood of patients. Buprenorphine
proved a satisfactory analgesic for postoperative use
by intramuscular injection.
S Air Med J 1987; 71: 359-361.
Morphine has been a standard postoperative analgesic for
many years. However, as a result of its potential for abuse and
its tendency to cause respiratory depression, the search has
been widened for safer agents. Agonist-antagonist agents have
less chance of causing these unwanted side-effects. 1 This new
group 'of drugs has agonistic action at some opiate receptor
sites and antagonistic action at others, the so-called dualism
effect. 2 This is said to explain the ceiling effect on respiratory
depression3 and may explain the ceiling effect on analgesia.2
BupreIiorphine (Temgesic; R & C Pharmaceuticals) is an
analgesic of this type. It is a highly lipophilic orcipavine
derivative of thebaine, similar in efficacy to morphine. 1,3 It can
be given by intramuscular or intravenous injection.
In order to ascenain whether this agent has advantages over
the time-tested morphine, a clinical trial was conducted to
compare these two agents in a busy hospital environment.
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Patients and methods
Patients over the age of 18 years graded as 1 or 2 on the American
Society of Anesthesiologists' scale scheduled for laparotomy or
onhopaedic surgery were selected for this study. They were
assigned to one of two groups by blind-card draw until there were
30 patients in each group. At a pre-operative visit it was explained
that analgesic efficacy was to be investigated in the postoperative
period and the methods of assessment were discussed.
As premedication, diazepam 0,15 mg/kg was given orally 2
hours before operation. A pentothal induction was used and suxa-
methonium 1 mg/kg was used for intubation. Maintenance of
anaesthesia was achieved with nitrous oxide, oxygen and halothane,
muscle relaxants being used where indicated. Thiny minutes
before the end of anaesthesia, a single dose of the test agent was
given intravenously. Thereafter, postoperative analgesia was given
at the request of the patient - 0,15 mg/kg morphine in one group
and 0,004 mg/kg buprenorphine in the other. In both groups the
analgesic was administered postoperatively by intramuscular injec-
tion into the gluteus maximus.
The ward nursing staff noted blood pressure, pulse and respira-
tion 2-hourly for 24 hours, baseline readings being those taken at
06hOO before surgery. Sedation and nausea were graded 2-hourly
on 4-point scales (sedation; awake (1), drowsy (2), asleep (3),
unrousable (4); and nausea: nausea (1), vomited 1- 2 times (2),
vomited 3 - 10 times (3), vomited> 10 times (4)). Side-effects,
especially unicaria and urine retention were looked for. The
number of injections given in the first 24 hours was noted.
Twenty-four hours postoperatively all patients were visited by
two of the investigators (K.P. and H.B.) who were not aware of
which analgesia the patient had received. The maximum and
minimum pain experienced during the test period was assessed by
the face scale (FS) and by the visual analogue scale (VAS). Mood
changes following analgesia were assessed as unchanged, feeling
good or feeling bad. Statistical analysis was done by the chi-square
test. A P value of < 0,05 was taken as significant.
Results
The two groups were comparable for sex, age, weight, duration of
anaesthesia and operations performed. The maximum pain felt in
this period assessed by the FS is shown in Table I, with buprenor-
phine significantly bener than morphine (P < 0,05).
The VAS also showed a significant difference (P < 0,05)
between the two groups in the maximum pain experienced (Table
II). The number of patients assessed on this scale is low as only
those who clearly comprehended this method were used for
statistical analysis.
There was no significant difference in minimal pain levels
experienced between the groups, or in the number of injections
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TABLE I. MAXIMUM PAIN EXPERIENCED ON THE FACE
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TABLE 11. MAXIMUM PAIN EXPERIENCED ON THE VISUAL
ANALOGUE SCALE
0-2 2-4 4-6
1 9 2
1 2 3
Buprenorphine
Morphine
Buprenorphine
Morphine
,. 1Ocm,------+j.1
I I
, I
INo pain on the left side
Fig. 1. Graphic representation of the mean systolic blood pres-
sures, diastolic blood pressures and pulse rates taken pre-
operatively and at 4, 8 and 12 hours postoperatively. The
buprenorphine values precede the morphine values.
Maximum imaginable pain on the right side
Buprenorphine
Morphine
required in the 24-hour test period, although 2 patients in the
buprenorphine group required no further analgesic after the intra-
operative dose and all in the morphine group required further
injections.
There was a higWy significant difference (P < 0,02) between the
two groups in terms of mood postoperatively (Table Ill).
Buprenorphine had less of an effect on mood than morphine,
. which tended to induce a good mood despite pain. Most buprenor-
\ phine patients did not experience any change of mood.
TABLE Ill. MOOD EXPERIENCED POSTOPERATlVELY
Good Unchanged Bad
6 22 2
15 12 3
Cardiovascular changes due to either analgesic were minimal
(Fig. 1). No clinical respiratory depression was seen. There were
no statistically significant differences in the side-effects experi-
enced. No patients had bad dreams or dysphoric reactions and 1
patient in each group had a mild skin itch., Sedation was not
noticeable in either group. Urine retention did not occur in any
uncatheterised patient. Nausea occurred in 15 of the buprenorphine
patients, 9 of whom vomited. Morphine caused nausea in 22
patients, 15 of whom vomited (0,05 < P > 0,1).
Discussion
Allowing the patient to be his own pain assessor is commonly
practised:,5 since pain is a very personal experience. The FS
was easily interpreted by all patients and is 'likely to be the
most reliable of the assessments. The VAS showed definite
differences between the two groups, but it was clearly poorly
understood by one-third of the patients and therefore its
usefulness is in doubt. Other studies have had similar problems
with the VAS.6
Buprenorphine is agonistic at J.L- and ()-receptors with some
antagonistic action at K-receptors. 7 It has a slow association!
dissociation receptor time,? which explains why its analgesic
activity outlasts its ,B-plasma half-life of 2 - 3 hours. Because of
this slow receptor association time, it was administered in this
study 30 minutes before the end of surgery. Thereafter, the
low receptor dissociation time would have allowed postopera-
tive follow-up injections to be given when pain became apparent
but before the analgesia had worn off significantly. This would
explain the finding that patients in the buprenorphine group
experienced a lower maximum level of pain than those in the
morphine group and would give patients some leeway if the
sister in a busy ward could not respond immediately. This
slow dissociation is said to give buprenorphine a more pro-
longed action than morphine, although this was not confirmed
by the number of postoperative injections patients received in
this study.
Alterations in mood will affect the interpretation of pain.8,9
Opiates may cause euphoria via J.L-receptors or dysphoria via 0-
receptors. 1 Mild euphoria would tend to make pain less
worrying for the patient. Mood elevation was more marked
with morphine, but despite this the analgesic properties of
buprenorphine proved bener. The lack of mood alteration is
probably a beneficial property in the modem world of potential
drug abuse.
The cardiovascular stability seen with buprenorphine is in
agreement with other studies,4-6 as is the lack of clinical
respiratory depression. 5•6 Nevertheless when respiratory
depression does occur it is reported to be difficult to reverse
with naloxone.6,lO Supportive ventilatory therapy is prererable
should this unusual complication occur.
Side-effects in this study were minimal and of no conse-'
quence. Drowsiness has been reported with buprenorphine6,lO
although other studies,11 including the present one, have not
noted this. A postulate is that this reported drowsiness might
indicate a lower level of pain causing less arousal of the
patient.
This trial showed buprenorphine to have bener postopera-
tive analgesic efficacy than morphine while having no significant
cardiovascular or respiratory effects at clinical dosage. There-
fore we feel justified in concluding that buprenorphine is an
effective postoperative analgesic.
Thanks to Mrs S. Venter for typing the manuscript, the anaes-
thetists and surgeons who allowed themselves to be bothered with
the extra paper work, and the ward nursing staff and the patients
for participating.
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sensitive immunoradiometric assay
serum thyroid-stimulating hormone
A
for
A first-line investigation for thyroid function
R. K. DESAI, I. JIALAL, M. A. K. OMAR, s. M. JOUBERT
Summary
The value of a highly sensitive immunoradiometric
assay for thyroid-stimulating hormone (TSH) in dis-
tinguishing between hyperthyroid patients arid normal
controls is discussed. The assay has a sensitivity of
0,3 J.LU/ml and correctly categorised all patients in
this study as either hyperthyroid or euthyroid. An
approach to thyroid function testing using this
sensitive TSH assay as a first-line investigation is
presented.
S Afr Med J1987; 71: 361-362.
Subjects and methods
Fasting TSH concentrations from the sera of 76 normal subjects
(51 women aged 19 - 57 years, 25 men aged 22 - 58 years) and 148
untreated thyrotoxic patients (130 women aged 20 - 74 years; 18
men aged 25 - 66 years) were measured. Thyrotoxicosis was
diagnosed on the basis of clinical symptoms and signs and elevated
serum free thyroxine (fT.) and free tri-iodothyronine (fT3) con-
centrations.
The Serono TSH Maiaclone is a solid phase immunoradiometric
assay (IRMA) employing three distinct high affiniry monoclonal
antibodies, two of these labelled with iodine-125 and the third
with fluorescein isothiocyanate (FITC). The three monoclonal
antibodies are premixed as a single liquid reagent. The fT. and
fT3 were measured by Amerlex Kit radio-immunoassays(Amersham International, UK).
Results
In a previous report l it was mentioned that a sensitive thyroid-
stimulating hormone (TSH) immunoassay could meet the
quest for a single thyroid function test which would correctly
categorise the majority of patients as hyper-, hypo-, or
euthyroid.
Until recently, most commercially available immunoassays
for TS,H lacked sufficient sensitivity to differentiate between
hyperthyroid and euthyroid patients. 2 Evaluation of a recently
commercialised assay, the Serono TSH Maiaclone, is described.
The analytical sensitiviry, calculated by analysing the zero standard
in replicate (20 times) and determining the two-standard deviation
value, was 0,3 J-lU/m!. The intra- and interassay coefficients of
variation of three controls run in 7 assays are shown in Table 1.
TSH concentrations were less than 0,5 J-lU/m! in the sera of all
148 thyrotoxic patients tested, and less than the analytical sensitiviry
(0,3 J-lU/m!) in 130 (88%). All euthyroid patients in the reference
group had a TSH concentration> 0,6 J-lU/m!. The range ofTSH
concentrations in the reference group was 0,6 - 4,1 J-lU/ml, with a
mean (± SD) of 1,82 ± 0,89 J-lU/m!.
Discussion
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The Serono TSH Maiaclone assay is a solid phase IRMA
employing three high affiniry monoclonal antibodies and
magnetic separation technology. This study demonstrates that
this rapid, sensitive TSH IRMA assay, with an analytical
sensitivity of 0,3 IlU/ml, can distinguish between the low
TSH found in hyperthyroid patients and TSH concentrations
found in normal controls. Although TSH was not undetectable
